Immunopharmacologic Monitoring of Therapeutic Serum Antibodies
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria for measurement of serum drug levels and anti-drug antibodies to guide management of biologic therapies, primarily for inflammatory bowel disease (IBD); specifies when testing is covered and not covered.
No material clinical or coverage changes in this revision.
Coverage Criteria
Anti-TNF testing in IBD
Covered when ANY of the following IBD-specific scenarios are met:
From policy indications; applies to anti-TNF therapies in IBD.
Vedolizumab/ustekinumab testing in IBD
Covered when ANY of the following IBD-specific scenarios are met:
From policy indications; applies to vedolizumab and ustekinumab in IBD.
Not medically necessary — outpatient non-IBD testing
Not covered when the following conditions apply:
Listed biologics: adalimumab, certolizumab, etanercept, golimumab, infliximab, infliximab-dyyb, infliximab-abda, rituximab, ustekinumab, vedolizumab.
TDM appropriateness for anti-TNFs
Consensus-based recommendations for when TDM is appropriate (from IBD-focused consensus statement):
Statements 1-4 reached high consensus for anti-TNFs
TDM appropriateness for vedolizumab and ustekinumab
Agent-specific appropriateness (consensus panel varying agreement):
Statements 5-8 show limited agreement for routine testing
Statements 11-12
Consensus thresholds and principles
General principles and specific concentration thresholds (consensus):
Statements 13-16
Statements 17-28
Agent-specific monitoring guidance
Guidance statements for drug concentration targets and detectability:
Supported by consensus statement (chunks 36)
Supported by consensus statement (chunk 37)
Testing for serum drug concentrations and anti-drug antibodies for anti-TNF therapies in individuals who do not have inflammatory bowel disease (including spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria. Requests for these tests in outpatient settings for non-IBD inflammatory conditions are therefore at risk of denial.
Measurement of serum drug levels and/or antibodies to specific biologic agents — including adalimumab, certolizumab, etanercept, golimumab, infliximab (and biosimilars), rituximab, ustekinumab, and vedolizumab — for any reason in an outpatient setting does not meet coverage criteria except where separate IBD-specific coverage criteria apply.
The NICE guidance (2016/2019) concluded that enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of TNF-alpha inhibitors show promise but that there is insufficient evidence to recommend their routine adoption. NICE recommends using ELISA testing in the context of research or data collection until further evidence is available.
For vedolizumab and ustekinumab, the consensus assessment found that available data are not adequate to define specific induction or maintenance concentration targets; the only consistent recommendation is to confirm the presence of a detectable drug when testing is used.
Use of drug and/or antibody concentration testing for anti-TNF therapies in non-IBD inflammatory conditions is considered not medically necessary because the literature does not demonstrate that these tests are required and beneficial for diagnosis or treatment in those populations.
Guideline panels vary: the AGA recommends reactive therapeutic drug monitoring in adults with active IBD (conditional, very low–quality evidence) and makes no recommendation for routine proactive TDM in quiescent IBD. The ACG advises that TDM should be considered when active disease is documented or in cases of nonresponse or loss of response, but does not endorse routine proactive monitoring for all patients in remission.
Current evidence does not support specifying induction or maintenance concentration targets for vedolizumab and ustekinumab beyond confirming that drug is detectable; the consensus statement notes that emerging data are insufficient to guide precise numeric thresholds.
Coding and Target Concentrations
| Use of therapeutic drug monitoring (measurement of drug and anti-drug antibody concentrations) to guide clinical decisions: dose intensification, optimization (e.g., increased dosing frequency), or switching therapies based on combined drug and antibody results (algorithmic approach). |
| Steenholdt et al. (2014): algorithm based on combined infliximab and anti-infliximab antibody measurements guided interventions and reduced costs versus routine infliximab dose escalation with similar disease control (58% vs 53%). | |
| Mitchell et al. (2016): TDM results grouped patients (low drug/high antibody; low drug/low antibody; therapeutic drug) and influenced management changes; appropriate changes were associated with a trend toward increased remission. | |
| Roblin et al. (2014): adalimumab trough levels and anti-adalimumab antibodies informed optimization vs switching; ADA trough >4.9 μg/mL associated with failure of two anti-TNFs and consideration of switching drug class. |
Provider Actions and Operational Notes
Limit testing to specified IBD clinical scenarios
Testing for serum drug concentrations and/or anti-drug antibodies for anti‑TNF agents is covered only for patients with inflammatory bowel disease (IBD) in the specified clinical scenarios: at the end of induction for all anti‑TNFs, at least once during maintenance, at the end of induction in primary non‑responders, and in patients with confirmed secondary loss of response. Testing for these agents for individuals without IBD (including spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria.
- Covered IBD scenarios: end of induction; at least once during maintenance; end of induction for primary non‑responders; confirmed secondary loss of response.
- Requests for anti‑TNF testing for non‑IBD outpatient indications are not covered and are at risk of denial.
No prior‑authorization rules specified in these sections
This policy document does not provide explicit prior authorization procedures or requirements for ordering drug/antibody concentration testing; the sections focus on clinical indications, evidence, and study results rather than a payer prior‑auth workflow.
- No prior authorization rules are specified in the extracted sections.
Verify prior‑auth requirements tied to policy effective date
Policy adoption effective date is 7/1/2023; providers should verify payer systems and any prior authorization rules that may be implemented referencing this policy effective date.
- Effective date: Adopted Avalon policy recommendation effective 7/1/2023.
Use TDM to guide dose intensification, optimization, or switching
Therapeutic drug monitoring (TDM) results (drug concentration and anti‑drug antibody measurements) can be used in clinical management to guide dose intensification, optimization, or switching therapies using algorithms that combine drug and antibody findings.
- Algorithms based on combined drug and antibody measurements informed cost‑effective interventions and influenced treatment changes in secondary infliximab failure (Steenholdt et al.).
- TDM grouping informed appropriate management changes and trends toward increased remission (Mitchell et al.).
Study operational details not specified here
The document does not specify operational study‑result procedures in this portion; studies describe associations between concentrations and outcomes and how those findings may influence switching or dosing decisions but do not define additional operational requirements here.
- Retrospective and cohort studies reported how drug concentrations correlated with outcomes and influenced switching or dosing but no additional operational study instructions are provided in these sections.
Therapeutic thresholds provided; no explicit step‑therapy rules
No explicit step‑therapy mandates are stated in these sections; the policy provides therapeutic concentration thresholds for certain agents (e.g., golimumab week‑6 ≥2.5 μg/mL and maintenance >1 μg/mL) and indicates for vedolizumab/ustekinumab the goal is simply to confirm detectable drug rather than specific numeric targets.
- Golimumab: minimum week 6 concentration ≥2.5 μg/mL; maintenance trough for remission >1 μg/mL.
- Vedolizumab/ustekinumab: evidence insufficient to specify induction/maintenance concentrations beyond confirming detectable drug.
Document IBD diagnosis and timing/clinical context
When requesting covered testing, document that the patient has inflammatory bowel disease and include the timing/context for testing (for example: end of induction, during maintenance, documented primary non‑response at end of induction, or confirmed secondary loss of response).
- Clinical indication and timing must be clearly stated to match the covered IBD scenarios (end of induction, maintenance, primary non‑response, or confirmed secondary loss of response).
Track post‑induction TDM and report trough findings for QI
Quality‑improvement initiatives should track post‑induction TDM rates and report trough level findings to inform dose optimization, as demonstrated by QI methods that increased post‑induction TDM and identified common subtherapeutic post‑induction infliximab levels.
- Example QI outcome: post‑induction infliximab TDM increased from 59% to 89% after interventions; adalimumab from 14% to 79%.
- Subtherapeutic post‑induction infliximab levels were common, indicating need for dose optimization.
Ensure LDT validation and maintain CLIA documentation
Labs performing laboratory‑developed tests (LDTs) for drug or antibody measurements must validate those tests and maintain CLIA documentation, since LDTs are regulated by CMS as high‑complexity tests and are not FDA‑cleared for clinical use.
- LDTs are regulated under CLIA '88 as high‑complexity tests; labs should maintain validation and CLIA documentation.
- FDA clearance/approval is not currently required for clinical use of LDTs, but validation is required by CLIA.
Testing for non‑IBD indications is not covered — risk of denial
Requests for drug and/or antibody concentration testing for anti‑TNF therapies for individuals without inflammatory bowel disease (including spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) do not meet coverage criteria and are at risk of denial.
- Testing for these drugs for non‑IBD outpatient indications is explicitly listed as not meeting coverage criteria.
No other explicit provider actions in this section
No additional provider actions are specified in this portion of the document beyond those summarized here.
- Sections state 'none explicitly stated' for other unspecified provider actions in the extracted text.
Government coverage supersedes policy — potential denial if conflict exists
If there is a conflict between this Policy and applicable government coverage (for example, Local Coverage Determinations, National Coverage Determinations, or state Medicaid rules), the government policy will be used to make the determination and such conflicts may lead to denial of the requested service.
- Providers should check applicable LCD/NCD/state Medicaid policies when they differ from this Policy.
Definitions
Background
TNF inhibitors and other biologic bDMARDs are widely used to treat immune-mediated inflammatory diseases but can elicit anti-drug antibodies that reduce efficacy or change drug exposure. Therapeutic drug monitoring (TDM)—measurement of trough drug concentrations and/or anti-drug antibodies—has strongest guideline support in inflammatory bowel disease where it can inform dose optimization, assessment of primary nonresponse, or evaluation of secondary loss of response. For some agents (e.g., infliximab, adalimumab, golimumab) consensus panels have proposed target trough concentrations, whereas for other agents (vedolizumab, ustekinumab) evidence is limited to demonstrating only a need to confirm detectable drug. Methods such as dried blood spot testing have validation guidance for small molecules but are not established for serum antidrug antibody testing.
Revision History
Policy adopted and became effective (Adopted Avalon policy recommendation).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.